Miller Edward B, Grosu Roy, Landau Zvi
Division of Rheumatology and the Department of Internal Medicine D, Kaplan Medical Center, POB 1, Rehovot, 76100, Israel.
Affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.
Clin Rheumatol. 2016 Jun;35(6):1655-7. doi: 10.1007/s10067-016-3253-6. Epub 2016 Apr 19.
G-CSF is a myeloid growth factor produced by monocytes, macrophages, fibroblasts, and endothelial cells. Clinical uses of G-CSF includes mobilization of peripheral blood progenitor cells from healthy donors before hematopoietic stem cell transplantation, acceleration of neutrophil recovery following chemotherapy, and in the management of neutropenia due to other causes including AIDS and genetic disorders of granulocyte production. G-CSF is well tolerated and reports to be safe in healthy donors, although follow-up studies are limited in duration (D'Souza et al. in Transfus Med Rev 22(4):280-290, 2008).Isolated abdominal aortitis (IAA) is a rare disorder most commonly caused by the large-vessel vasculitides giant cell arteritis (GCA) and Takayasu arteritis, although it may also be associated with several other rheumatologic diseases and infections (Gornik and Creager in Circulation 117:3039-3051, 2008). To our knowledge, there only two cases have been published of IAA occurring in patients who had received G-CSF therapy (Dariea et al. in Rev Med Interne 25(3):225-229, 2004; Adiga et al. in Clin Drug Investig 29:821-825, 2009).We describe a case of a 55-year-old male, with peripheral vascular disease who after receiving Neupogen (G-CSF) developed a latent case of IAA. After further investigation and exclusion of other possible causative factors, we conclude that the most probable etiology is induction by G-CSF.
粒细胞集落刺激因子(G-CSF)是一种由单核细胞、巨噬细胞、成纤维细胞和内皮细胞产生的髓系生长因子。G-CSF的临床用途包括在造血干细胞移植前动员健康供体的外周血祖细胞、化疗后加速中性粒细胞恢复,以及用于治疗包括艾滋病和粒细胞生成遗传性疾病在内的其他原因引起的中性粒细胞减少症。G-CSF耐受性良好,据报道对健康供体是安全的,尽管后续研究的持续时间有限(D'Souza等人,《输血医学评论》22(4):280-290,2008年)。孤立性腹主动脉炎(IAA)是一种罕见疾病,最常见的病因是大血管血管炎巨细胞动脉炎(GCA)和高安动脉炎,尽管它也可能与其他几种风湿性疾病和感染有关(Gornik和Creager,《循环》117:3039-3051,2008年)。据我们所知,仅有两例接受G-CSF治疗的患者发生IAA的病例已发表(Dariea等人,《内科医学评论》25(3):225-229,2004年;Adiga等人,《临床药物研究》29:821-825,2009年)。我们描述了一例55岁男性外周血管疾病患者,在接受优保津(G-CSF)治疗后发生了潜伏性IAA。经过进一步调查并排除其他可能的致病因素后,我们得出最可能的病因是G-CSF诱导。